Phathom Pharmaceuticals
PHAT
94 hedge funds and large institutions have $237M invested in Phathom Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 32 increasing their positions, 23 reducing their positions, and 9 closing their positions.
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
39% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 23
13% more funds holding
Funds holding: 83 → 94 (+11)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
11.04% less ownership
Funds ownership: 81.03% → 69.98% (-11%)
32% less capital invested
Capital invested by funds: $350M → $237M (-$113M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$11.2M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$5.87M |
| 3 |
MVM
Medicxi Ventures Management
St. Helier,
Jersey
|
+$3.94M |
| 4 |
NM
Newtyn Management
New York
|
+$2.63M |
| 5 |
BlackRock
New York
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$9.35M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$8.99M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.07M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$595K |
PHAT Hedge Fund Activity: Q2 2022 in Review
94 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q2 2022, worth a combined $237M — down 32% from $350M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PHAT positions and 9 closed out — a net gain of 12 holders — while 32 added to existing stakes and 23 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $11.2M. The largest seller was Janus Henderson Group, cutting an estimated $9.35M.
- 94 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q2 2022, up from 83 in Q1 2022.
- Funds reported $237M of Phathom Pharmaceuticals stock for Q2 2022, down 32% quarter-over-quarter.
- 21 funds opened new Phathom Pharmaceuticals positions in Q2 2022 and 9 closed out, a net change of +12 holders.
- The largest Phathom Pharmaceuticals buyer in Q2 2022 was 683 Capital Management, an estimated $11.2M added.
- The largest Phathom Pharmaceuticals seller in Q2 2022 was Janus Henderson Group, an estimated $9.35M sold.
Based on aggregated 13F filings for Q2 2022.